3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Classical hematology
1
Conditions
Venous Thrombosis
1
Venous Thromboembolism
1
Pulmonary Embolism
1
Gastrointestinal Neoplasms
1
Interventions
pembrolizumab
33
Carboplatin
18
Cisplatin
15
Nivolumab
14
Pemetrexed
12
Paclitaxel
12
Ipilimumab
11
atezolizumab
10
Gemcitabine
10
venetoclax
9
Radiotherapy
9
Docetaxel
9
durvalumab
8
Cyclophosphamide
8
fludarabine
7
Specimen Handling
7
Biopsy
7
Bevacizumab
7
tislelizumab
6
enzalutamide
6
Trastuzumab
6
Practice Guidelines as Topic
6
Cetuximab
6
tazemetostat
5
fludarabine phosphate
5
Surveys and Questionnaires
5
Standard of Care
5
Radiosurgery
5
Magnetic Resonance Spectroscopy
5
Injections
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
MAA868
×
90 days
×
Clear all
NCT05171075
2026-04-17
MAGNOLIA
Anthos Therapeutics, Inc.
Phase 3
Terminated
417 enrolled